GlassScriptPhysician profile
Amanda Roberts
NPI 1891466843
$5,113.71
in general payments reported to CMS, 2019-2025
27 companies · $1,490 in 2025
The $1,490 reported for 2025 was more than what 88% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $226 · 2022: $806 · 2023: $1,149 · 2024: $1,443 · 2025: $1,490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,082.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,081.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,224.31 | 2021-2025 | |
| Alkermes, INC. | $749.54 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $455.43 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $347.87 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $312.47 | 2023-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $290.06 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Supernus Pharmaceuticals, INC. | $240.91 | 2025 | Qelbree |
| Lundbeck LLC | $231.82 | 2022-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $198.82 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $174.41 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $152.24 | 2023-2024 | Austedo Xr, Uzedy, Austedo |
| Corium, LLC | $126.88 | 2023-2025 | Azstarys |
| Neos Therapeutics, LP | $100.55 | 2024-2025 | Adzenys Xr-Odt, Exxua |
| Noven Therapeutics, LLC | $91.67 | 2023-2025 | Xelstrym, Secuado |
| Sunovion Pharmaceuticals INC. | $64.50 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $60.98 | 2023-2025 | Sublocade, Perseris |
| Takeda Pharmaceuticals U.S.A., INC. | $52.71 | 2024-2025 | Trintellix |
| Tris Pharma INC | $38.80 | 2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $33.40 | 2023-2024 | Jornay Pm |
| Scilex Pharmaceuticals INC. | $31.75 | 2024 | |
| Braeburn INC. | $28.59 | 2025 | Brixadi |
| Owp Pharmaceuticals, INC. | $22.13 | 2024 | Subvenite |
| E.R. Squibb & Sons, L.L.C. | $21.77 | 2025 | Cobenfy |
| Orexo US, INC. | $16.00 | 2025 | Zubsolv |
| Vertical Pharmaceuticals, LLC | $15.67 | 2024 | Relexxii |
| Almatica Pharma LLC | $15.55 | 2025 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $14.88 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.